Esophageal Squamous Cell Carcinoma

191

Pipeline Programs↗

122

Active Trials↗

65

Companies Involved↗

Esophageal Squamous Cell Carcinoma is a highly competitive landscape with 191 programs across 65 companies. The most active players are Eastern Cooperative Oncology Group, LaNova Medicines Zhejiang Co., Ltd., BeiGene. 3 therapies are approved with 37 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

61/100

Mech. Concentration

10/100

Completion Rate

77/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Eastern Cooperative Oncology Group

1 program

LaNova Medicines Zhejiang Co., Ltd.

1 program

BeiGene

4 programs

Risen (Suzhou) Pharma Tech Co., Ltd.

2 programs

Jiangsu Simcere Pharmaceutical Co., Ltd.

2 programs

Boehringer Ingelheim

2 programs

Pipeline

Programs by Phase

Preclinical26

Toripalimab

Coherus Oncology, Inc.

Trilaciclib

Pharmacosmos A/S

Immune Checkpoint Inhibitors

Peking Union Medical College Hospital

Neoadjuvant Chemotherapy

Japan Clinical Oncology Group

Immunotherapy

Bristol-Myers Squibb

Phase 111

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Apatinib

LaNova Medicines Zhejiang Co., Ltd.

BYL719

Novartis

Dose Extension

Institute of Hematology & Blood Diseases Hospital, China

JMT101

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2114

Pyrotinib

Hengrui Therapeutics, Inc.

Lapatinib

GSK

Fluzoparib

Risen (Suzhou) Pharma Tech Co., Ltd.

Ivonescimab

Summit Therapeutics

Abemaciclib

Eli Lilly

Phase 337

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Docetaxel

Avyxa

Serplulimab

Shanghai Henlius Biotech

Tiragolumab

Roche

Approved3

Celecoxib

Philadelphia Eye Associates

Metformin

EMD Serono

Nab-Paclitaxel，cisplatin

Yang Jianjun, PhD

Analysis

Modality Breakdown

82%

Small molecule

191 of 233 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 233 classified programs, each share of the total. Modality classified for 98% of 242 pipeline programs.

Analysis

Trial Status

239

clinical trials

Unknown status69 · 29%

Recruiting66 · 28%

Completed37 · 15%

Not yet recruiting35 · 15%

Active, not recruiting15 · 6%

Terminated8 · 3%

Other9 · 4%

Clinical Trials

Trial Activity

239 trials

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 3·NCT05495152·219 enrolled

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Recruiting·PPeking University·Phase 2·NCT06684600·35 enrolled

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

Recruiting·PPeking University·Phase 1·NCT06690476·74 enrolled

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Recruiting·WWest China Hospital·Phase 1·NCT06225921·6 enrolled

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06698692·200 enrolled

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Recruiting·SShandong Boan Biotechnology Co., Ltd·Phase 3·NCT06022861·510 enrolled

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·—·Phase 2·NCT06356688·30 enrolled

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Recruiting·SSichuan University·Phase 2·NCT06446726·30 enrolled

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Recruiting·RRuijin Hospital·Phase 2·NCT06122493·48 enrolled

Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Recruiting·SShanghai Zhongshan Hospital·N/A·NCT07054086·30 enrolled

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03736863·147 enrolled

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT07086469·69 enrolled

An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting·TThree Gorges Hospital of Chongqing University·N/A·NCT07080437·40 enrolled

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT06843889·34 enrolled

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06509568·92 enrolled

Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)